Secukinumab survival and long‐term efficacy in patients with plaque psoriasis: real‐life data from a tertiary hospital in Greece
- 3 September 2018
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (2) , E82-E84
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort StudyActa Dermato-Venereologica, 2018
- Drug survival of secukinumab for psoriasis in a real-world settingJournal of Dermatological Treatment, 2018
- Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective studyJournal of the American Academy of Dermatology, 2018
- Treatment optimization with secukinumab 150 mg for moderate‐to‐severe psoriasis in clinical practice: a single‐center open‐label 52‐week studyInternational Journal of Dermatology, 2018
- Long‐term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single‐center experienceThe Journal of Dermatology, 2017
- Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasisTherapeutic Advances in Chronic Disease, 2017
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasisBritish Journal of Dermatology, 2017
- Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentaryJournal of the American Academy of Dermatology, 2017
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)Journal of the American Academy of Dermatology, 2015
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014